全文获取类型
收费全文 | 11393篇 |
免费 | 626篇 |
国内免费 | 449篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 316篇 |
妇产科学 | 93篇 |
基础医学 | 1223篇 |
口腔科学 | 55篇 |
临床医学 | 1483篇 |
内科学 | 3321篇 |
皮肤病学 | 66篇 |
神经病学 | 490篇 |
特种医学 | 148篇 |
外国民族医学 | 1篇 |
外科学 | 441篇 |
综合类 | 1635篇 |
预防医学 | 1117篇 |
眼科学 | 83篇 |
药学 | 1399篇 |
1篇 | |
中国医学 | 453篇 |
肿瘤学 | 127篇 |
出版年
2024年 | 21篇 |
2023年 | 179篇 |
2022年 | 321篇 |
2021年 | 429篇 |
2020年 | 399篇 |
2019年 | 351篇 |
2018年 | 372篇 |
2017年 | 297篇 |
2016年 | 291篇 |
2015年 | 261篇 |
2014年 | 643篇 |
2013年 | 931篇 |
2012年 | 506篇 |
2011年 | 611篇 |
2010年 | 496篇 |
2009年 | 458篇 |
2008年 | 539篇 |
2007年 | 506篇 |
2006年 | 412篇 |
2005年 | 391篇 |
2004年 | 393篇 |
2003年 | 351篇 |
2002年 | 292篇 |
2001年 | 249篇 |
2000年 | 242篇 |
1999年 | 198篇 |
1998年 | 205篇 |
1997年 | 254篇 |
1996年 | 216篇 |
1995年 | 174篇 |
1994年 | 165篇 |
1993年 | 141篇 |
1992年 | 113篇 |
1991年 | 114篇 |
1990年 | 90篇 |
1989年 | 91篇 |
1988年 | 85篇 |
1987年 | 77篇 |
1986年 | 60篇 |
1985年 | 78篇 |
1984年 | 70篇 |
1983年 | 56篇 |
1982年 | 55篇 |
1981年 | 48篇 |
1980年 | 49篇 |
1979年 | 37篇 |
1978年 | 29篇 |
1977年 | 27篇 |
1976年 | 27篇 |
1975年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
81.
健康成人血液流变学与血脂相关性的实验研究 总被引:1,自引:0,他引:1
目的:研究健康成人血液流变学指标与血脂之间的相关性。方法:抽取西安市某单位健康查体人群各项检查结果齐全的资料117例,其中男性79例,女性38例,将采集的数据进行统计分析。结果:男性和女性之间,TG、HBV、LBV、HRV、LRV、CV、CY均有显著差异(P〈0.05);女性资料中,血脂指标与血液流变学指标的相关性无统计学意义(P〉0.05);男性资料中,血液流变学指标与血脂指标有相关性(P〈0.05)。结论:控制血液粘度和血脂水平是防止和减低心脑血管疾病发生的重要环节。 相似文献
82.
磷酸盐型低密度脂蛋白亲和吸附剂制备与体外吸附试验研究 总被引:1,自引:0,他引:1
研究目的是制备低密度脂蛋白亲和吸附剂,用于去除高脂血症患者血液中高含量的低密度脂蛋白。首先以悬浮分散法制备壳聚糖微球和纤维素微球载体,然后固定磷酸吡哆醛和磷酸盐配基,制备出三种吸附剂,并进行体外静态吸附性能测试。结果表明,壳聚糖-磷酸吡哆醛吸附剂对LDL最大吸附量为1.30mg/mL,磷酸盐型壳聚糖和纤维素吸附剂对LDL的最大吸附量分别为2.72mg/mL和3.12mg/mL,并且吸附量随配基含量的增加呈增大趋势,3种吸附剂对高密度脂蛋白均无明显吸附。对吸附剂的灭菌和储存稳定性的研究表明,磷酸盐型纤维素吸附剂具有较好的稳定性。本研究第一次报道磷酸盐型低密度脂蛋白吸附剂。 相似文献
83.
Jean Bergeron Thierry Normand Adl Bharucha M. R. van Murtby Pierre Julien Claude Gagné Carole Dionne Marc de Braekeleer Daniel Brun Michael R. Hayden Paul J. Luplen 《Clinical genetics》1992,41(4):206-210
Familial lipoprotein lipase deficiency (FLD) is of particular interest to the French Canadian population of Québec since the largest concentration of homozygotes and carriers of this genetic disease in the world resides in this area. We have previously described a missense mutation (M-188) in the lipoprotein lipase (LPL) gene which was present in FLD patients belonging to different ancestries, including a number of French Canadians (Monsalve MV et al. J Clin Invest 1990: 86: 728-734). In the present report, we show that this mutation, although found in largest absolute numbers among French Canadians as compared to other groups in the world, accounts for only a small proportion (24%) of all the LPL mutant alleles in this population. The M-188 occurs either in the homozygote state or as a compound heterozygote with another LPL mutation. Analysis of geographic distribution indicates that the M-188 is more prevalent in western Québec, with the highest carrier rate in the Mauricie region. Genealogical reconstruction leads to the recognition of four founders for M-188, all emigrants from France to Québec in the 17th century. 相似文献
84.
The deletion (D) allele of an insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE) has been reported to be an independent risk factor for myocardial infarction (MI), particularly in people lacking traditional risk factors. Furthermore, a borderline association between Lp(a) lipoprotein level and the I/D polymorphism at the ACE locus was reported in one study. We have searched for possible "level gene" or "variability gene" effects of ACE genes on Lp(a) lipoprotein, total cholesterol (TC), high density lipoprotein (HDL) cholesterol (HDLC), low density lipoprotein (LDL) cholesterol (LDLC), triglycerides (TG), apolipoprotein B (apoB), apolipoprotein A-I (apoA-I), and body mass index (BMI). None of these variables differed significantly between genotypes in the I/D polymorphism in any of three population samples. A single population sample created by combining the three series, exhibited an insignificant trend towards individuals carrying the D-allele having a higher level of Lp(a) lipoprotein than those lacking it, and DD homozygotes had a significantly higher Lp(a) lipoprotein level than the combined group of ID/II individuals (p = 0.03). These results may indicate that the D-allele of the I/D polymorphism at the ACE locus could influence the level of Lp(a) lipoprotein. 相似文献
85.
Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance 总被引:8,自引:0,他引:8
The results of two previous and two recent studies of middle-aged males and females are presented to exemplify the clinical importance of lipoprotein (a) (Lp(a)) as a risk factor for atherosclerosis and coronary heart disease. In these studies various conventional and recently suggested risk factors were included and different methods for Lp(a) quantification were used. Lp(a) was a significant risk factor in all four studies. In the recent prospective case-control study, Lp(a) and cholesterol were found to act synergistically and predict primary acute myocardial infarction in Swedish males. A cholesterol level above 6.5 mmol/1 increased the risk of acute myocardial infarction if the Lp(a) level was above 200 mg/1. The plasma apo A-I level was a protective factor. In the other recent case-control study, an Lp(a) level above 500 mg/1 was a highly significant risk factor in Black and White US women with myocardial infarction or advanced coronary artery disease in addition to low density lipoprotein cholesterol levels above 130 mg/dl. A high apo A-I level was a protective factor. In these studies no other factors tested reached significance in multivariate logistic regression analysis. A hypothetical association between high Lp(a) levels and intracellular infection with Chlamydia pneumoniae is discussed. The results suggest that the Lp(a) level is useful in identifying high-risk individuals. Lowering low density lipoprotein cholesterol below 100 mg/dl (7lt;2.6 mmol/1) seems to be most important in both males and females with high-risk Lp(a) levels. 相似文献
86.
Analysis of the mechanism of lipoprotein(a) assembly 总被引:2,自引:0,他引:2
Marlys L. Koschinsky Santica M. Marcovina Lorraine F. May Brent R. Gabel 《Clinical genetics》1997,52(5):338-346
We have assessed the ability of a battery of purified recombinant apolipoprotein(a) (r-apo(a)) derivatives to bind to immobilized low-density lipoprotein (LDL) by ELISA. Removal of the apo(a) kringle IV type 8 and type 9 sequences dramatically reduced apo(a) binding to LDL. The binding of apo(a) to LDL was effectively inhibited by arginine, lysine, the lysine analogue ε-aminocaproic acid and proline; comparable inhibition was observed using the 17K and KIV5–8 r-apo(a) derivatives, suggesting a direct role for sequences contained in the latter species in mediating the initial non-covalent interactions which precede specific disulfide bond formation. We also determined that r-apo(a) binds directly to a synthetic apoB peptide spanning amino acid residues 3732–3745; this interaction appeared to be mediated by sequences present in apo(a) kringle IV types 8 and 9, and could be inhibited by arginine, lysine and proline. The results of this study indicate that the efficiency of Lp(a) assembly is a direct function of the initial non-covalent interactions between apo(a) and LDL; in addition, these studies suggest that Cys3734 in apoB mediates covalent linkage with apo(a) by virtue of the ability of the apoB sequences surrounding this residue to directly interact with apo(a) KIV type 9. 相似文献
87.
Restriction site polymorphism at the LPA (Lp(a) apoliprotein; apoliprotein(a)) locus 总被引:1,自引:0,他引:1
A restriction site polymorphism in the Lp(a) apolipoprotein gene (the LPA gene) is reported. The basis for the polymorphism is presence or absence of an MspI restriction site that appears to be 3' to the last kringle IV structure of the gene. The "1" gene (presence of the restriction site) has a frequency of 0.316 and the "2" gene (absence of the restriction site) has a frequency of 0.684. Both members of each of 67 monozygotic (MZ) twin pairs had the same genotype and there was Mendelian segregation of the DNA variants in 40 families with a total of 75 children. There was a lower proportion of people with genotype 1-1 in the top quartile than in the 3 bottom quartiles of the population distribution of Lp(a) lipoprotein levels but the difference did not reach statistical significance. 相似文献
88.
Samuels ME Forbey KC Reid JE Abkevich V Bulka K Wardell BR Bowen BR Hopkins PN Hunt SC Ballinger DG Skolnick MH Wagner S 《Clinical genetics》2001,59(2):88-98
Defects in the lipoprotein lipase (LPL) gene are associated with dyslipidemia in the general population. Several rare mutations in the gene, as well as two common coding region polymorphisms, D9N and N291S, exhibit deleterious effects on circulating lipid levels. Using a linkage-based approach, we have identified a large Utah kindred segregating the D9N variant in the LPL gene. The kindred was ascertained for premature coronary heart disease and was expanded based on familial dyslipidemia. A genomic scan identified a region of linkage including LPL, and mutation screening identified the segregating variant. In the kindred, the variant shows high penetrance for a hypoalphalipoproteinemia phenotype, but is also associated with hypertriglyceridemia and elevated insulin levels. The strength of linkage was dependent on the combination of phenotype definition and model parameters, favoring the use of a MOD score approach. Most other studies of LPL have proceeded by mutation screening of randomly chosen individuals or selected affected probands; this is the first example identifying a segregating LPL mutation using direct linkage. 相似文献
89.
本文观察了体外丙二醛(MDA),铜离子(Cu2+氧化修饰的脂蛋白(a)[Lp(a)]结构和生物学性质的变化。氧化修饰Lp(a)过氧化程度增高,负电荷增加,易被巨噬细胞—清道夫受体识别和摄取。MDA修饰Lp(a)出现新的MDA-LDL位点;同纤维蛋白溶酶原(Pg)竞争抑制试验显示氧化、修饰Lp(a)同Pg同源性增加。提示载脂蛋白(a)状态同动脉粥样硬化的病理过程有关。 相似文献
90.
S. A. Kurilovich E. V. Pozdeeva A. P. Serdyuk I. O. Svetlova Yu. A. Shakhov 《Bulletin of experimental biology and medicine》1990,110(6):1660-1663
Institute of Therapy, Siberian Branch, Academy of Medical Sciences of the USSR, Novosibirsk. All-Union Preventive Medicine Research Center, Ministry of Health of the USSR, Moscow. (Presented by Academician of the Academy of Medical Sciences of the USSR Yu. P. Nikitin.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 110, No. 12, pp. 611–613, December, 1990. 相似文献